TBIO Telesis Bio Inc

On March 26, 2020, Translate Bio, Inc. (the “Company”) issued a press release to announce that due to the COVID-19 pandemic response, the Company anticipated interruptions in enrollment, dosing and follow-up in the ongoing Phase 1/2 clinical trial for MRT5005 in patients with cystic fibrosis, and that the Company would provide an update when it had additional insight into enrollment and dosing metrics given the uncertain and dynamic nature of the situation. Enrollment and dosing in the clinical trial have been paused as a consequence of the response to the COVID-19 pandemic. As previously disclosed, the Company plans to provide updated timing on the expected interim data readout of the additional single-ascending dose (“SAD”) group and the multiple-ascending dose (“MAD”) portion of the clinical trial at a later date.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the Company’s expectations on when it will report interim data from the additional SAD group and the MAD portion of the Phase 1/2 clinical trial of MRT5005; and the Company’s plans, strategies and prospects for its business, including its lead development programs. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forward,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: the Company’s ability to resume enrollment and dosing in its Phase 1/2 clinical trial of MRT5005 and timing thereof; the Company’s ability to advance the development of its platform and programs under the timelines it projects, demonstrate the requisite safety and efficacy of its product candidates and replicate in clinical trials any positive findings from preclinical studies; the content and timing of decisions made by the U.S. Food and Drug Administration, other regulatory authorities and investigational review boards at clinical trial sites, including decisions as it relates to ongoing and planned clinical trials; the Company’s ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the availability of significant cash required to fund operations; competitive factors; the COVID-19 pandemic; general economic and market conditions and other important risk factors set forth under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission on March 12, 2020 and in any other subsequent filings made by the Company. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.